We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics- Hematology Division

Download Mobile App





D-Dimer Test Can Still Help Rule Out Pulmonary Embolisms in Hospitalized COVID-19 Patients

By LabMedica International staff writers
Posted on 27 Oct 2021
Print article
Image: D-Dimer Test (Photo courtesy of USF Health)
Image: D-Dimer Test (Photo courtesy of USF Health)

The D-dimer test can still be helpful in ruling out pulmonary embolisms in hospitalized COVID-19 patients, according to a new study.

Researchers at the University of South Florida Health Morsani College of Medicine (USF Health; Tampa, FL, USA) conducted a single-center, diagnostic study to investigate how well D-dimer testing performed at excluding pulmonary embolism in patients hospitalized with COVID-19. They found that the screening blood test originally validated in seriously ill patients without COVID-19 is still clinically useful for ruling out pulmonary embolism in patients hospitalized with the coronavirus.

Pulmonary embolisms occur when blood clots that form in another part of the body (often the leg), travel through the bloodstream, and lodge in the blood vessels of the lung, decreasing blood flow and causing low oxygen levels. Research indicates COVID-19 patients are three to 10 times more likely to develop pulmonary embolisms than other hospitalized patients, even when they are not as seriously ill or immobilized. Scientists are still investigating why, but it appears the COVID-19 virus may create a cellular environment that promotes clotting by making the inside of blood vessels uneven, irritated, and prone to microtears.

Doctors who suspect pulmonary embolisms routinely rely on widely available D-dimer screening to rule out the potentially life-threatening blood clotting disorder – most commonly in surgical patients immobilized for long periods and patients admitted to intensive care units. D-dimer is a simple blood test that measures protein fragments of blood clots floating in the bloodstream. D-dimer levels, normally undetectable or detectable at very low levels, rise sharply when the body is breaking down the clots. A negative D-dimer test (one that rules out pulmonary embolism) can help patients avoid more expensive, invasive diagnostic tests, like a computed tomography pulmonary angiogram, or CTPA.

The USF Health researchers wondered if the increased risk for blood clotting in COVID-19 patients, and uncertainty of diverse D-dimer values found in earlier smaller studies, reduced the existing screening tool’s ability to correctly rule out pulmonary embolism in COVID patients. The conventional thinking was that D-dimer levels would almost always be high in COVID-19 patients, therefore the test as originally validated (in non-COVID patients) would not be accurate at differentiating COVID patients without clots.

The restrospective study looked at the records of 1,541 patients hospitalized with COVID-19 at Tampa General Hospital from Jan. 1, 2020, to Feb. 5, 2021. They compared plasma D-dimer concentrations with CTPA, the criterion for diagnosing pulmonary embolism, in 287 of those patients. All COVID-19 patients with CTPA evidence of pulmonary embolism had D-dimer levels of 0.05 μg/mL or greater, as did the majority (91.2%) of patients without CTPA evidence of pulmonary embolism. (Concentrations of 0.05 μg/mL and higher are considered positive for pulmonary embolism, while anything below that D-dimer level is negative). The researchers also analyzed whether changing the cutoff levels defining positive or negative D-dimer test results specifically for the COVID patient population might improve the test’s performance.

Within the limitations of this single-center study, setting higher D-dimer thresholds was associated with improved specificity – but at “the cost of an increased false-negative rate that could be associated with an unacceptable patient safety risk,” the study authors wrote. A false-negative result means that the test does not detect a pulmonary embolism when the serious blood clotting problem is very likely present. While clinicians must maintain heightened suspicion for pulmonary embolisms when evaluating symptoms in COVID-19 patients, the overall USF Health study results indicate that the currently available D-dimer test adequately screens for the likelihood of pulmonary embolism in hospitalized COVID patients.

“Our study found that clinicians can feel confident interpreting the D-dimer levels the same in COVID patients as they do in every other patient; we don’t need a special (different) value for COVID patients,” said principal investigator Asa Oxner, MD, associate professor and vice chair of USF Health Internal Medicine. “So, in hospitalized COVID patients, we can appropriately rule out a pulmonary embolism if d-dimer levels are low.”

“The mechanisms of developing pulmonary embolisms may differ for COVID patients, but the resulting physiology is the same for all patients. The little fragments of (undissolved) blood clots are still detectable with D-dimer,” said Oxner.

Related Links:
USF Health 

Gold Supplier
SARS-CoV-2 IGRA
SARS-CoV-2 IGRA
New
Gold Supplier
Centrifuge
Multifuge X4 Pro Centrifuge Series
New
Auto Multiparameter POC Analyzer
Triage MeterPro
New
Anti-SARS-CoV-2 Controls Kit
ACCURUN Anti-SARS-CoV-2 Controls Kit

Print article

Channels

Hematology

view channel
Image: Atellica Solution (Photo courtesy of Siemens Healthineers)

Siemens Introduces New Intelligent, Integrated IVD Solutions Virtually at EUROMEDLAB 2021

Siemens Healthineers (Erlangen, Germany) introduced new intelligent, integrated IVD solutions virtually at the XXIV IFCCEFLM European Congress of Clinical Chemistry and Laboratory Medicine (EuroMedLab... Read more

Immunology

view channel
Image: The Luminex 200 Instrument System sets the standard for multiplexing, providing the ability to perform up to 100 different tests in a single reaction volume on a flow cytometry-based platform (Photo courtesy of Luminex Corp)

Inflammatory Cytokines Measured in Infants Born to Preterm Preeclamptic Mothers

Preeclampsia is both a vascular and inflammatory disorder. The pathophysiology of preeclampsia is complex and rooted in the interplay between maternal and placental factors with the key characteristics... Read more

Microbiology

view channel
Image: The sciREADER CL2 enables high quality digital colorimetric imaging of various support formats (Photo courtesy of SCIENION)

Multiplex Immunoassay Developed for Confirmation and Typing of HTLV Infections

Human T-Cell Lymphotropic Viruses (HTLV) type 1 and type 2 account for an estimated five to 10 million infections worldwide and are transmitted through breast feeding, sexual contacts and contaminated... Read more

Pathology

view channel
Image: The Ventana BenchMark Ultra autostainer is for cancer diagnostics with automation and the test menu include IHC, ISH, and FITC tests (Photo courtesy of Ventana Medical System)

Specific Biomarker Investigated for Triple-Negative Breast Cancer Diagnosis

Triple-negative breast cancer (TNBC) is defined by the lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression and comprises a heterogeneous... Read more

Technology

view channel
Image: PKeye Workflow Monitor System (Photo courtesy of PerkinElmer, Inc.)

PerkinElmer’s New Cloud-Based Platform Enables Laboratory Personnel to Remotely Manage Its Instruments in Real-Time

PerkinElmer, Inc. (Waltham, MA; USA) has launched its PKeye Workflow Monitor, a cloud-based platform enabling laboratory personnel to remotely manage and monitor their PerkinElmer instruments and workflows... Read more

Industry

view channel
Illustration

Global Lateral Flow Assay Market to Reach Nearly USD 6.5 Billion by 2031 Due to Surge in Demand for Rapid POC Testing

The global lateral flow assay market is projected to grow at a CAGR of around 5% from USD 3.7 billion in 2020 to over USD 6.4 billion by 2031, driven by the growing adoption of home-based lateral flow... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.